M. Coppens MD PhD

Scientific staff member (UD)
Main activities
Patient care, Research
Vascular Medicine with an emphasis on Thrombosis and Haemostasis/Haemophilia
Focus of research

Management of bleeding in patients treated with anticoagulation and the role of specific antidotes.

Absorption of rivaroxaban and management of patients with short bowel syndrome.

Gene Therapy in patients with severe haemophilia A or B.

Biomarkers to predict joint damage in patients with severe haemophilia

Key publications
  • Miesbach W, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens R, Tangelder M, Castaman G, Schwäble J, Bonig H, Seifried E, Cattaneo F, Meyer C, Leebeek FWG, Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. BLOOD 2018;131 (9):1022-1031 [PubMed]
  • Cheung YW, Barco S, Mathôt RAA, van den Dool EJ, Stroobants AK, Serlie MJ, Middeldorp S, Coppens M, Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. THROMB RES 2017;160:76-82 [PubMed]
  • Cheung YW, Barco S, Hutten BA, Meijers JCM, Middeldorp S, Coppens M, In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J THROMB HAEMOST 2015;13 (10):1799-1805 [PubMed]
  • Barco S, Whitney Cheung Y, Coppens M, Hutten BA, Meijers JCM, Middeldorp S, In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. BRIT J HAEMATOL 2016;172 (2):255-261 [PubMed]
  • Coppens M, Reijnders JH, Middeldorp S, Doggen CJM, Rosendaal FR, Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J THROMB HAEMOST 2008;6 (9):1474-1477 [PubMed]
All Publications
Research programmes


M. Coppens MD PhD

PhD Students
A. Abdi MD
Drs. R. Bavalia MD
I.M. Bistervels
F.R. Kloosterman
A. Zwagemaker

Prof. dr. S. Middeldorp MD PhD (Vascular Medicine)

Other research related activities
  • Contribution to guidelines and protocols, Antithrombotic Therapy 2016
  • Contribution to guidelines and protocols, Blood transfusion, subgroup on platelet transfusion 2017
  • Contribution to guidelines and protocols, ASHguideline on venous thromboembolism, subgroup on Thrombophilia 2016-2018
  • Membership of medical or scientific committee, Trombosestichting, Scientific advisory board
  • Speakers bureau / Lectures, various pharmaceutical companies including Bayer, CSL Behring
  • Membership of advisory board / Consultant, Daiichi Sankyo
  • Membership of advisory board / Consultant, CSL Behring
Current research funding
  • BAYER B.V.
  • Bayer Healthcare Pharmaceuticals Inc.
  • CSL Behring GmbH
  • Erasmus MC
  • Leiden University Medical Centre
  • McMaster University Medical Centre
  • UniQure Biopharma BV
  • ZonMw